Compare CXAIW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAIW | IDYA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | CXAIW | IDYA |
|---|---|---|
| Price | $0.04 | $33.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $49.18 |
| AVG Volume (30 Days) | 20.9K | ★ 904.3K |
| Earning Date | 03-21-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,200,000.00 | ★ $214,834,000.00 |
| Revenue This Year | N/A | $2,662.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $0.11 | $13.45 |
| 52 Week High | $0.14 | $37.08 |
| Indicator | CXAIW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 47.74 |
| Support Level | $0.03 | $34.04 |
| Resistance Level | $0.05 | $35.28 |
| Average True Range (ATR) | 0.02 | 1.07 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 32.37 | 22.76 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.